Moderna's oncology franchise has been repriced by the Merck-partnered INTerpath-001 melanoma vaccine trial, a watershed moment. Argus upgraded the stock to Buy with a $180 target, noting shares remain more than 70% below their old highs, and Moderna closed an upsized $2.6 billion convertible note to fund oncology growth. The stock is consolidating in a tight pennant after its biggest gap up in years; a move above $156.13 targets $161.37, then $176.66. x.com 

Moderna could re-rate toward $210 by the end of 2027 because the market should move ahead of its free cash flow inflection. That assumes free cash flow reaches breakeven by mid-2028, driven by successful commercialization of its personalized mRNA cancer therapy. x.com 

Moderna looks expensive even under a bullish scenario. A base model values Covid, flu and RSV at $10B, oncology at $15B and the platform at $5B: a $30B market cap, or $75 a share versus $135, about 45% downside. Even $10B of oncology sales by 2035, one of the best pharma launches ever, at 8x sales and a 10% discount rate gives about $120. The CMV trial failed, norovirus is at risk, rivals are developing mRNA flu vaccines, and BofA's raised $170 target looks unjustified. x.com  x.com  x.com  x.com  … Show more

Moderna could get explosive above $200 as anyone who shorted last week's valuation downgrade has to cover. The shakeout on that downgrade was a killer opportunity, and the stock is now back over $200. x.com 

Tempus AI is being repriced because its acquisition of Personalis benefits directly from positive Moderna news, while short covering is still underway. Short interest is about 30 million shares, over eight days of normal 3-5 million share volume, and the three-day surge absorbed under a third of it. A small market cap makes the stock easy to push higher, and bullish divergences on the three-day and weekly charts usually last weeks to months. Resistance sits at 74-76, 80 and 84-86. x.com  x.com  … Show more

Moderna's cash burn and persistent operating losses make profitable commercialization the central constraint despite promising melanoma results. Its revenue remains too small and uneven to cover development costs, while rising diluted shares weaken financial resilience. x.com 

Moderna's cancer-cure mystery and optimism are the conditions that drive big stock moves. Its theme is now hot to trade, alongside related stocks. CoreWeave's 2025 AI data-center IPO rode similar uncertainty about AI revenue while AI was hot; it now faces AI-spending worries. x.com 

Moderna looks likely to stay relatively stable above its gap-up price into next year, as big buyers return. A $6M sale of March 2027 $110 puts bets on exactly that, which seems logical. Yesterday's $30B was the second-largest dollar buy volume ever for the stock, after buy volumes had already re-emerged; January's buying, the largest since Q2 2024, came when the stock was above $100, versus about $50 now. x.com  x.com 

Moderna's data catalyst is done, and it won't get an early stop in RCC. That makes it a good short here, with the story over until at least next summer. x.com 

Moderna is extremely attractive because curing cancer is a big story, but more consolidation is likely first. The weekly chart shows a wide gap between price and the upper Bollinger Band, so volatility may need another week or two to ebb before the stock possibly starts moving higher. x.com